Mutual of America Capital Management LLC Sells 301 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Mutual of America Capital Management LLC reduced its position in Quest Diagnostics Incorporated (NYSE:DGX) by 2.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 13,739 shares of the medical research company’s stock after selling 301 shares during the period. Mutual of America Capital Management LLC’s holdings in Quest Diagnostics were worth $2,133,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio raised its stake in Quest Diagnostics by 0.6% in the 1st quarter. Public Employees Retirement System of Ohio now owns 70,656 shares of the medical research company’s stock valued at $9,405,000 after acquiring an additional 409 shares during the period. Zurich Insurance Group Ltd FI acquired a new stake in shares of Quest Diagnostics during the 1st quarter worth about $1,531,000. Janus Henderson Group PLC boosted its holdings in shares of Quest Diagnostics by 126.0% during the 1st quarter. Janus Henderson Group PLC now owns 37,305 shares of the medical research company’s stock worth $4,966,000 after buying an additional 20,800 shares during the period. B. Riley Wealth Advisors Inc. raised its holdings in Quest Diagnostics by 19.7% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 2,022 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 333 shares during the period. Finally, Levin Capital Strategies L.P. acquired a new stake in Quest Diagnostics during the first quarter worth approximately $628,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total transaction of $304,987.40. Following the transaction, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. This represents a 14.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Michael J. Deppe sold 18,755 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the transaction, the chief accounting officer now owns 34,941 shares in the company, valued at $5,382,661.05. The trade was a 34.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,520 shares of company stock valued at $3,472,728 in the last 90 days. Corporate insiders own 0.79% of the company’s stock.

Quest Diagnostics Stock Down 0.2 %

Shares of DGX opened at $163.59 on Monday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.25. Quest Diagnostics Incorporated has a 52 week low of $123.04 and a 52 week high of $165.10. The stock has a market capitalization of $18.26 billion, a price-to-earnings ratio of 21.99, a PEG ratio of 2.83 and a beta of 0.89. The stock has a fifty day moving average of $154.84 and a 200-day moving average of $148.37.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.26 by $0.04. Quest Diagnostics had a return on equity of 15.25% and a net margin of 8.82%. The business had revenue of $2.49 billion during the quarter, compared to analysts’ expectations of $2.43 billion. During the same quarter in the prior year, the firm earned $2.22 EPS. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 8.9 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 29th. Shareholders of record on Tuesday, January 14th will be issued a $0.75 dividend. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $3.00 dividend on an annualized basis and a yield of 1.83%. Quest Diagnostics’s payout ratio is presently 40.32%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. StockNews.com lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, November 18th. Mizuho lifted their target price on Quest Diagnostics from $160.00 to $174.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Baird R W upgraded shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 23rd. Barclays lifted their price objective on shares of Quest Diagnostics from $154.00 to $168.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 23rd. Finally, UBS Group boosted their price target on Quest Diagnostics from $165.00 to $166.00 and gave the company a “neutral” rating in a research note on Wednesday, October 23rd. Nine investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Quest Diagnostics currently has an average rating of “Hold” and an average price target of $164.58.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.